Breakthrough Brain Cancer Treatment VORANIGO Added to Australian PBS, Slashing Costs
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
Australians living with rare, incurable brain cancers now have access to a groundbreaking new treatment, VORANIGO (vorasidenib), thanks to its listing on the Pharmaceutical Benefits Scheme (PBS) from August 1, 2026. This marks the first new subsidised treatment in over two decades for specific cancers like Grade 2 IDH-mutant astrocytoma and oligodendroglioma, drastically cutting patient costs from around $28,000 per month to just $25 per prescription. The move offers fresh hope to approximately 135 Australians diagnosed each year with these challenging conditions, which often affect younger adults in their most productive years. This pivotal development comes after years of persistent advocacy from patients, clinicians, and research groups, highlighting the urgent global need for advanced brain cancer therapies. While VORANIGO targets IDH-mutant gliomas, distinct from the glioblastoma battled by the late Professor Richard Scolyer, his high-profile case and courageous participation in experimental treatments underscored the critical importance of accelerating scientific progress in brain cancer research. The listing follows VORANIGO Therapeutic Goods Administration (TGA) approval in September 2023 and a previous rejection by the Pharmaceutical Benefits Advisory Committee (PBAC) in July 2025 before a recommendation in March of this year. Healthcare professionals, including Associate Professor Jim Whittle from Peter MacCallum Cancer Centre, see this as a vital new 'tool in the toolbox' for managing complex, long-term conditions, potentially delaying the need for more aggressive treatments like radiotherapy or chemotherapy. This PBS listing not only improves accessibility and affordability but also sends a powerful message about the impact of collaborative efforts in driving medical innovation. The focus now shifts to ensuring eligible patients can access this targeted therapy and continuing the fight for more breakthroughs across the spectrum of brain cancers.